Log in
Enquire now
‌

US Patent 8372802 Fluorinated macrocyclic compounds as hepatitis C virus inhibitors

Patent 8372802 was granted and assigned to Enanta Pharmaceuticals on February, 2013 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Current Assignee
Enanta Pharmaceuticals
Enanta Pharmaceuticals
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
83728020
Patent Inventor Names
Yat Sun Or0
Yonghua Gai0
Zhe Wang0
Date of Patent
February 12, 2013
0
Patent Application Number
124074610
Date Filed
March 19, 2009
0
Patent Citations Received
‌
US Patent 11912714 Spiropyrrolidine derived antiviral agents
0
‌
US Patent 11993600 Saturated spirocyclics as antiviral agents
0
‌
US Patent 11976084 Spiropyrrolidine derived antiviral agents
0
‌
US Patent 11970502 Macrocyclic antiviral agents
0
‌
US Patent 11858945 Alkyne-containing antiviral agents
0
‌
US Patent 11919910 Spiropyrrolidine derived antiviral agents
0
Patent Primary Examiner
‌
Thomas Heard
0
Patent abstract

The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof:

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 8372802 Fluorinated macrocyclic compounds as hepatitis C virus inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.